These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6814086)

  • 21. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro.
    Neal RA; van Bueren J
    Trans R Soc Trop Med Hyg; 1988; 82(5):709-14. PubMed ID: 3075357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trypanocidal drugs and the role of kidney forms of Trypanosoma (Herpetosoma) musculi in immunity of mice against reinfection.
    Dusanic DG
    Z Parasitenkd; 1985; 71(1):19-31. PubMed ID: 3984449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rapid development of drug-resistance by Trypanosoma evansi in immunosuppressed mice.
    Osman AS; Jennings FW; Holmes PH
    Acta Trop; 1992 Feb; 50(3):249-57. PubMed ID: 1348601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple drug resistance in Trypanosoma vivax in the Tana River District of Kenya.
    Röttcher D; Schillinger D
    Vet Rec; 1985 Nov; 117(21):557-8. PubMed ID: 4082427
    [No Abstract]   [Full Text] [Related]  

  • 26. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
    Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
    BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benzonidazole and nifurtimox].
    Andrade SG; Magalhães JB; Pontes AL
    Rev Soc Bras Med Trop; 1989; 22(3):113-8. PubMed ID: 2518608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo trypanocidal activity of the ethyl esters of N-allyl and N-propyl oxamates using different Trypanosoma cruzi strains.
    Aguirre-Alvarado C; Zaragoza-Martínez F; Rodríguez-Páez L; Nogueda B; Baeza I; Wong C
    J Enzyme Inhib Med Chem; 2007 Apr; 22(2):227-33. PubMed ID: 17518350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Reyes PA; Vallejo M
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004102. PubMed ID: 16235350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiparasitic nitroimidazoles. 9. Synthesis of some 2-(4-dialkylaminomethylstyryl)-and 2-(4-amidinostyryl)5-nitro-1-vinylimidazoles.
    Ross WJ; Jamieson WB
    J Med Chem; 1975 Apr; 18(4):430-2. PubMed ID: 804556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 33. Susceptibility of a rodent-adapted strain of Trypanosoma vivax to Berenil, Samorin and Novidium.
    Arowolo RO; Ikede BO
    Acta Trop; 1977 Mar; 34(1):61-4. PubMed ID: 16467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recommendations for diagnosis, treatment and follow-up of the Trypanosoma cruzi: human immunodeficiency virus co-infection].
    Rev Soc Bras Med Trop; 2006; 39(4):392-415. PubMed ID: 17119760
    [No Abstract]   [Full Text] [Related]  

  • 35. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple drug-resistant bovine trypanosomes in South Darfur Province, Sudan.
    Mohamed-Ahmed MM; Rahman AH; Abdel Karim EI
    Trop Anim Health Prod; 1992 Aug; 24(3):179-81. PubMed ID: 1304666
    [No Abstract]   [Full Text] [Related]  

  • 38. RNA-interference silencing of the adenosine transporter-1 gene in Trypanosoma evansi confers resistance to diminazene aceturate.
    Witola WH; Inoue N; Ohashi K; Onuma M
    Exp Parasitol; 2004; 107(1-2):47-57. PubMed ID: 15208037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.
    Andrade SG; Magalhães JB; Pontes AL
    Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chagas' disease: a search for treatment and a question--should the disease be of military concern?
    Kinnamon KE; Poon BT; Scovill JP; Hanson WL; Waits VB
    Mil Med; 1997 Aug; 162(8):527-32. PubMed ID: 9271903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.